ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP94-20 Commercial Pharmacy Benefit Exclusion for Condylox®, Lyumjev™, Veregen® and Zilxi™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 14, 2020
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2461 - 2470 လၢ 4139 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP102-20 Introducing eviCore’s new intelliPath® Technology
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 14, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
BC-COM_SiteofService-Infused-Injected_DrugProgram_Comm_2020-1006.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Upcoming policies effective November 2_ 2020.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Upcoming policies effective November 30_ 2020.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P76-20 2021 Renewal Changes Summary for Institutional Providers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2020 October Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP81-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Risdiplam PA with QL
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 26, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP79-20 Introducing the Blue Cross Blue Shield System’s New National High-Performance Network
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 26, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP64R1-20 Medical Drug Update for New to Market Viltolarsen (Viltepso)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 26, 2020